Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome

<div>Mean daily defined doses (DDDs) of gabapentinoids (a) and tricyclic antidepressants (TCA) (b) and also percent of the maximum dose of serotonin-norepinephrine reuptake inhibitors (SNRIs) (c) 2 y before and 1 y after disability pension (DP) in persistent spinal pain syndrome patients with spinal cord stimulation at KUH. Gabapentinoid users <i>n</i> = 12, TCA users <i>n</i> = 8, and SNRI users <i>n</i> = 6. The mean DDD was calculated as the average of total purchased drugs during the specific six-month period (months: 0–6; 6–12; 12–18; 18–24 before and 0–6; 6–12 after DP). For SNRI drugs, the DDD/day of drug use was related to the maximum daily dose of the same drug. The maximum dose was 120 mg/day for duloxetine and 375 mg/day for venlafaxine.</div>

Pain Research and Management

fig2

Figure 2

Figure 2: Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome 

Figure 2 | Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome 